Nalaganje...
Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?
To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A [n = 40], B [n = 60], and C [n = 143]) according to the proximity of their gastrointesti...
Shranjeno v:
| izdano v: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6406298/ https://ncbi.nlm.nih.gov/pubmed/30781391 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020230 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|